A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder

Journal of Psychiatric Research

Volumn 45, Issue 6, 2011, Pages 748-755

  Pangallo, Beth ^a   Dellva, Mary Anne ^a   D'Souza, Deborah N ^b   Essink, Beal ^c   Russell, James ^a   Goldberger, Celine ^a  

^a ELI LILLY AND COMPANY   (United States)

^b i3 Statprobe   (United States)

^c Oregon Center Clinical Investigation   (United States)

Author keywords

Efficacy; LY2216684; Major depressive disorder; Norepinephrine; Safety

Indexed keywords

EDIVOXETINE; NORADRENALIN UPTAKE INHIBITOR; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; ERECTILE DYSFUNCTION; FEMALE; HAMILTON SCALE; HEART RATE; HUMAN; HYPERHIDROSIS; INSOMNIA; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

EID: 79955889045     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2011.03.014     Document Type: Article

References (35)

1. [APA] American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Association, Washington, DC, (DSM-IV). 4th ed.
2. [APA] American Psychiatric Association Diagnostic and statistical manual of mental disorders 2000, American Psychiatric Association, Washington, DC, text revision (DSM-IV-TR). 4th ed.
3. Cymbalta [package insert] 2010, Eli Lilly and Company, Indianapolis.
4. Dubé S., Dellva M.A., Jones M., Kielbasa W., Padich R., Saha A., et al. A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression. Journal of Psychiatric Research 2010, 44:356-363.
5. Edronax [package insert] 2008, Hertzliya Pituach: Pharmacia, Italy.
6. Effexor XR [package insert] 2009, Wyeth Pharmaceuticals Inc., Philadelphia.
7. EuroQol A new facility for the measurement of health-related quality of life. Health Policy 1990, 16:199-208. The EuroQol Group.
8. Fava M., Graves L.M., Benazzi F., Scalia M.J., Iosifescu D.V., Alpert J.E., et al. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. Journal of Clinical Psychiatry 2006, 67:1754-1759.
9. Fava M., Kaji J. Continuation and maintenance treatments of major depressive disorder. Psychiatric Annals 1994, 24:281-290.
10. [FDA] Food & Drug Administration Guidance for industry-patient-reported outcome measures: use in medical product development to support labeling claims 2009, Food & Drug Administration, Silver Spring, MD.
11. Goddard A.W., Ball S.G., Martinez J., Robinson M.J., Yang C.R., Russell J.M., et al. Current perspectives of the roles of the central norepinephrine system in anxiety and depression. Depression and Anxiety 2010, 27:339-350.
12. Greden J.F. The burden of disease for treatment-resistant depression. Journal of Clinical Psychiatry 2001, 62(Suppl. 16):26-31.
13. Greden J.F. Unmet need: what justifies the search for a new antidepressant?. Journal of Clinical Psychiatry 2002, 63(Suppl. 2):3-7.
14. Guy W. Clinical global impressions ECDEU assessment manual for psychopharmacology, revised (DHEW Publ. No. ADM 76-338) 1976, National Institute of Mental Health, Rockville, MD, 218-222.
15. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry 1960, 23:56-62.
16. Kielbasa W., Quinlan T., Lachno R., Bredt D., Dubé S. Pharmacodynamics of LY2216684: evaluation of peripheral and central norepinephrine transporter inhibition using 3,4-dihydroxyphenylglycol as a biomarker of pharmacologic activity 2010, Presented at the 49th Annual Meeting of the American College of Neuropsychopharmacology, Miami Beach, Florida.
17. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., et al. National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the national Comorbidity Survey Replication (NCS-R). Journal of the American Medical Association 2003, 289:3095-3105.
18. Lexapro [package insert] 2009, Forest Pharmaceuticals, Inc, St. Louis.
19. Marcus S.M., Young E.A., Kerber K.B., Kornstein S., Farabaugh A.H., Mitchell J., et al. Gender differences in depression: findings from the STAR*D study. Journal of Affective Disorders 2005, 87:141-150.
20. Mendoza T.R., Wang X.S., Cleeland C.S., Morrissey M., Johnson B.A., Wendt J.K., et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 1999, 85:1186-1196.
21. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979, 134:382-389.
22. Montgomery S.A. Reboxetine: additional benefits to the depressed patient. Journal of Psychopharmacology 1997, 11(4 Suppl.):S9-S15.
23. Moos R.H., Cronkite R.C. Symptom-based predictors of a 10-year chronic course of treated depression. Journal of Nervous and Mental Disease 1999, 187:360-368.
24. Pae C.U., Lim H.K., Han C., Patkar A.A., Steffens D.C., Masand P.S., et al. Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion. Expert Review of Neurotherapeutics 2007, 7:1251-1263.
25. Phillips G.A., Matza L., Murray L., Revicki D.A. Reliability and validity of the fatigue associated with depression questionnaire (FAsD): an interim analysis. European Journal of Neurology 2009, 16(Suppl. 3):460.
26. Posner K. State of the science: measurement of suicidal adverse events and the Columbia suicide severity rating scale 2007, NCDEU, Boca Raton, FL.
27. Rush A.J., Trivedi M.H., Ibrahim H.M., Carmody T.J., Arnow B., Klein D.N., et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biological Psychiatry 2003, 54:573-583.
28. Sartorius N., Angstt J. Suicide in population subgroups. International Clinical Psychopharmacology 2001, 16(Suppl. 2). 2 p. preceding S1.
29. Sheehan D.V. The anxiety disease 1983, Scribner, New York.
30. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 1998, 59(Suppl. 20):22-33.
31. Stahl S.M., Zhang L., Damatarca C., Grady M. Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. Journal of Clinical Psychiatry 2003, 64(Suppl. 14):6-17.
32. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., et al. STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. American Journal of Psychiatry 2006, 163:28-40.
33. Williams J.B.W., Kobak K.A., Bech P., Engelhardt N., Evans K., Lipsitz J., et al. The GRID-HAMD: standardization of the Hamilton Depression Rating Scale. International Clinical Psychopharmacology 2008, 23:120-129.
34. Wolfe F. Fatigue assessments in rheumatoid arthritis: comparative performance of visual analog scales and longer fatigue questionnaires in 7760 patients. Journal of Rheumatology 2004, 31:1896-1902.
35. World Health Organization 2010 WHO Initiative on depression in Public health 2010, WHO, World Health Organization, Geneva, Switzerland, [accessed on 12. 02. 2010]. http://www.who.int/mental_health/management/depression/definition/en/print.html.